Last $0.05 USD
Change Today 0.00 / 0.00%
Volume 42.0K
CORX On Other Exchanges
Symbol
Exchange
OTC US
As of 5:10 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

cortex pharmaceuticals inc (CORX) Snapshot

Open
$0.05
Previous Close
$0.05
Day High
$0.05
Day Low
$0.05
52 Week High
10/7/14 - $0.09
52 Week Low
12/12/13 - $0.02
Market Cap
6.8M
Average Volume 10 Days
64.3K
EPS TTM
$-0.04
Shares Outstanding
144.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CORTEX PHARMACEUTICALS INC (CORX)

Related News

No related news articles were found.

cortex pharmaceuticals inc (CORX) Related Businessweek News

No Related Businessweek News Found

cortex pharmaceuticals inc (CORX) Details

Cortex Pharmaceuticals, Inc. engages in the discovery and development of pharmaceuticals for the treatment of respiratory disorders. The company is also involved in clinical development in the areas of neurological and psychiatric disorders. It develops ampakine compounds comprising CX1739 for the treatment of patients with central and mixed sleep apnea, and CX1942 to be used in an injectable formulation as a rescue medication for the emergency treatment of drug-induced respiratory depression. The company was founded in 1987 and is based in Glen Rock, New Jersey.

2 Employees
Last Reported Date: 10/14/14
Founded in 1987

cortex pharmaceuticals inc (CORX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cortex pharmaceuticals inc (CORX) Key Developments

Cortex Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

Cortex Pharmaceuticals, Inc. filed its 10-K on Oct 14, 2014 for the period ending Dec 31, 2012. In this report its auditor, Haskell & White LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Cortex Pharmaceuticals, Inc. Names John Greer as Chairman of the Scientific Advisory Board

Cortex Pharmaceuticals, Inc. announced the appointment of John Greer, Ph.D. as Chairman of the Company's Scientific Advisory Board, which is currently in formation. Dr. Greer is the Director of the Neuroscience and Mental Health Institute at the University of Alberta. He is an Alberta Innovates Health Sciences Senior Scientist and holds grants in two primary areas of research pertaining to neuromuscular control of breathing. Dr. Greer is the inventor of the use patents licensed by Cortex for the use of ampakines that the Company is developing for the treatment of drug-induced respiratory depression and central and mixed-sleep apnea.

Cortex Pharmaceuticals, Inc. Announces Appointment of Two Directors

Cortex Pharmaceuticals, Inc. announced that James E. Sapirstein and Kathryn MacFarlane have joined the board of directors of the company as independent directors. James E. Sapirstein has been the Chief Executive Officer and director of ContraVir Pharmaceuticals, Inc. Ms. MacFarlane is currently an owner and Managing Partner of SmartPharma LLC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORX:US $0.05 USD 0.00

CORX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amorfix Life Sciences Ltd C$0.13 CAD +0.005
Eli Lilly & Co $68.12 USD +0.80
Novartis AG SFr.93.50 CHF +0.50
Pfizer Inc $31.15 USD +0.05
View Industry Companies
 

Industry Analysis

CORX

Industry Average

Valuation CORX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 140.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 120.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORTEX PHARMACEUTICALS INC, please visit www.cortexpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.